Gabapentin News and Research

RSS
Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain.
Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Researchers investigate effects of neuromodulatory medication on orofacial tissue

Researchers investigate effects of neuromodulatory medication on orofacial tissue

Unmet medication need in neuropathic pain

Unmet medication need in neuropathic pain

Perampanel does not offer added benefit for patients with Epilepsy

Perampanel does not offer added benefit for patients with Epilepsy

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

XenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis

Study determines effectiveness of gabapentin for treatment of vulvodynia in women

Study determines effectiveness of gabapentin for treatment of vulvodynia in women

XenoPort reports net loss of $19.1 million for fourth quarter 2013

XenoPort reports net loss of $19.1 million for fourth quarter 2013

FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

FDA-approved drug pregabalin effectively treats RLS symptoms with less side effects

Study sheds light on the biological underpinnings of obesity

Study sheds light on the biological underpinnings of obesity

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Doctors should consider underlying inflammatory conditions when selecting anti-epilepsy drugs, say researchers

Depomed reports financial results for third quarter 2013

Depomed reports financial results for third quarter 2013

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

FDA accepts NDA for MNK-795 oral formulation

FDA accepts NDA for MNK-795 oral formulation

Depomed receives complete response letter for SEFELSA NDA

Depomed receives complete response letter for SEFELSA NDA

XenoPort's Arbaclofen placarbil fails to meet co-primary endpoints in Phase 3 clinical trial

XenoPort's Arbaclofen placarbil fails to meet co-primary endpoints in Phase 3 clinical trial

Nearly 1/10 stroke patients suffer from chronic and debilitating pain

Nearly 1/10 stroke patients suffer from chronic and debilitating pain

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Restless legs syndrome and insomnia: a possible explanation

Restless legs syndrome and insomnia: a possible explanation

Anti-seizure drug benefits women with severe morning sickness

Anti-seizure drug benefits women with severe morning sickness

Spaniels' neuropathic pain condition stays static without surgery

Spaniels' neuropathic pain condition stays static without surgery